Adaptive Polymersome and Micelle Morphologies in Anticancer Nanomedicine: From Design Rationale to Fabrication and Proof‐of‐Concept Studies. Issue 8 (4th September 2018)

• Record Type: Journal Article
• Authors: Pijpers, Imke A. B.; Abdelmohsen, Loai K. E. A.; Xia, Yifeng; Cao, Shoupeng; Williams, David S.; Meng, Fenghua; van Hest, Jan C. M.; Zhong, Zhiyuan
• Is Part Of: Advanced therapeutics. Volume 1:Issue 8(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-04
• Subjects: adaptive morphologies -- drug delivery -- nanomedicine -- nanotechnology; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.201800068
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Intrigued and inspired by the intricacy of natural architectures which display various morphologies, researchers seek to develop artificial counterparts in order to replicate, and thereby harness, their function for diverse applications. In particular, well‐defined nanoparticles with various morphologies are of great interest for biomedical research. The impact of morphologically discrete nanoparticles upon the development of nanomedicine is significant, gaining increasing attention for its potential to provide a new avenue for the development of future therapeutic technologies. This progress report discusses adaptive morphologies based on block copolymers as platforms for therapeutic and smart drug delivery applications, including design rationale and controlling the morphology of polymeric nanoparticles. The proof‐of‐concept studies on influence of shapes of nanoparticles on their anticancer effects in vitro and in vivo are addressed. Abstract : The impact of morphologically discrete nanoparticles upon the performance of nanomedicine is an important topic, gaining increasing attention for its potential to provide a new avenue for the development of future therapeutic technologies. This progress report focuses on the utility of adaptive morphologies in anticancer nanomedicine. Design rationale, fabrication, and proof‐of‐concept in vitro and in vivo studies are discussed.